Wednesday, April 118th, 2018, Baltimore, MD - Insilico Medicine, a Baltimore-based company specializing in the application of artificial intelligence for drug discovery, biomarker development and aging research, announces the presentation of its Africa AI, Blockchain and Longevity Consultant, Iraneus Ogu, at the International Conference on e-Education, e-Business, e-Management and e-Learning (ICEBML-18), April 19, 2018, Johannesburg, South Africa.
Ogu's talk "Building the African pharmaceutical industry and the future of longevity with next-generation artificial intelligence" will cover the latest advances in AI tending to commence a revolution in African biopharmaceutical industry and become a growth engine for R&Din local pharmaceutical companies. The presentation will also be dedicated to the challenges of African pharmaceutical sector and to the educational opportunities for building the strong local teams interested in the application of AI to drug discovery.
"We are very happy to present our work at the ICEBML-18, which bring together many African experts from pharmaceutical and biotech industry as well as from education. The topic of Artificial Intelligence for pharma R&D is rapidly gaining popularity and we are happy to be at the leading edge of research and one of the innovation drivers in this area", said Alex Zhavoronkov, PhD, the founder and CEO of Insilico Medicine, Inc.
"The digital revolution in healthcare provided the tremendous amount of data that are generated daily, and these data could be used for development of various healthcare products. There is a strong need to develop better solutions to many global healthcare challenges, especially to many local challenges in Africa. In Insilico we aim to converge the advances in next-generation artificial intelligence and blockchain to accelerate the development of multiple products for healthcare needs", said Iraneus Ogu, Africa AI, Blockchain and Longevity Consultant of Insilico Medicine, Inc.
The ICEBML-18 is an international conference devoted to the advancement of theory and practices in education. The event gathers the prominent experts promoting the collaborative excellence between academicians and professionals from Education. The conference organizers aim to provide an international platform to engage developers and researchers in the scientific discussion about current research and latest advances in engineering and technology that facilitate the exchange of new ideas in Africa. The event will transpire on April 19, 2018.
###
Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first who applied deep generative adversarial networks (GANs) to the generation of new molecular structures with specified parameters and published seminal papers in Oncotarget and Molecular Pharmaceutics. The paper published in Molecular Pharmaceutics in 2016 demonstrated the proof of concept of the application of deep neural networks for predicting the therapeutic class of the molecule using the transcriptional response data, received the American Chemical Society Editors' Choice Award. A recent paper published in November 2017 described the application of the next-generation AI and blockchain technologies to return the control over personal data back to the individual. One of the latest papers published in the Journals of Gerontologydemonstrated the application of the deep neural networks to assessing the biological age of the patients. The most recent paper published in Oncotarget presented the roadmap to enhancing radioresistance for space exploration and colonization.
For further information, images or interviews, please contact:
Official Conference Websites: http://researchsociety.
About Insilico Medicine, Inc
Insilico Medicine, Inc. is an artificial intelligence company headquartered at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore, with R&D and management resources in Belgium, Russia, UK, Taiwan and Korea sourced through hackathons and competitions.
The company utilizes advances in genomics, big data analysis, and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI and Aging.AI and operates Chemistry.AI intended to capture the tacit knowledge of medicinal chemists.
Through a partnership with the BitFury Group, the company is working on a range of AI solutions for blockchain to help return the power over life data back to the individual. The company raised venture capital and partnered with Juvenescence Limited, a holding company focused on longevity biotechnology. The company aspires to become the "Bell Labs" for artificial intelligence and associated technologies for healthcare and longevity biotechnology and commercialize its research by forming subsidiaries around the specific technologies and licensing the intellectual property, molecules and data to the biotechnology and pharmaceutical companies. In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. Brief company video: https:/
No comments:
Post a Comment